Targeting Tumor-Related Immunosuppression Using Metronomic Cyclophosphamide in Combination With Lenalidomide -New Mechanisms for Old Drugs

Chemotherapy: Open Access
doi 10.4172/2167-7700.1000e110
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

OMICS Publishing Group

Related search

A Phase II Study to Evaluate Lenalidomide in Combination With Metronomic-Dose Cyclophosphamide in Patients With Heavily Pretreated Classical Hodgkin Lymphoma

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2015English

Trastuzumab in Combination With Metronomic Cyclophosphamide and Methotrexate in Patients With HER-2 Positive Metastatic Breast Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2006English

Targeting CD38 Alleviates Tumor-Induced Immunosuppression

Oncotarget
Oncology
2017English

New Drugs for Old Targets

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

New Drugs for Mental Diseases?: New Diseases for Old Drugs?

Journal of the Royal Society of Medicine
Medicine
1987English

Anti-Tumor Innate Immunity Activated by Intermittent Metronomic Cyclophosphamide Treatment of 9L Brain Tumor Xenografts Is Preserved by Anti-Angiogenic Drugs That Spare VEGF Receptor 2

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2014English

Combination of Aromatase Inhibitors With Metronomic Capecitabine: A New Chemoendocrine Treatment for Advanced Breast Cancer

Journal of Cancer Therapy
2019English

Metronomic Cyclophosphamide Schedule-Dependence of Innate Immune Cell Recruitment and Tumor Regression in an Implanted Glioma Model

Cancer Letters
Cancer ResearchOncology
2014English

Old Drugs, New Concerns

Journal for Nurse Practitioners
LPNFundamentalsSkillsAdvancedLVNSpecialized Nursing
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy